Bronchogen Nasal Spray
20 mg of the Khavinson tetrapeptide Ala-Glu-Asp-Leu (AEDL) as a sterile solution in bacteriostatic water, in a metered spray bottle. Made from a peptide lot tested in the manufacturer’s own laboratory, with a certificate.
| Compound | Bronchogen Ala-Glu-Asp-Leu (AEDL); Khavinson bronchial peptide bioregulator |
|---|---|
| CAS number | Not assigned |
| Molecular formula | C18H30N4O9 |
| Theoretical mass | 446.5 Da |
| Sequence / structure | H-AEDL-OH (4 residues; free N- and C-termini) |
| Contents | Bronchogen: 20 mg per bottle (≤ 0.2% w/v) |
| Form | Sterile aqueous solution in bacteriostatic water (0.9% benzyl alcohol), supplied in a metered nasal spray bottle |
| Storage, sealed | Store at 2–8 °C, protected from light; do not freeze |
| Format | Solution in a metered nasal spray bottle |
Sizes and lots
- 20 mg · 1 bottle — $118.99
- 20 mg · Kit of 10 — $1057.82
Bronchogen nasal spray contains Ala-Glu-Asp-Leu, the 446.5 Da tetrapeptide that the Khavinson series links to the bronchi and lungs. The bottle holds 20 mg of Bronchogen as a sterile solution in bacteriostatic water, at no more than 0.2% w/v by the safety data sheet. Research on the peptide covers bronchial cell cultures, DNA melting and docking models. A separate literature on nasal drug delivery deals with peptides in general and has not examined this one.
What is in the bottle
Each bottle carries 20 mg of AEDL, the tetrapeptide also offered as powder in the Bronchogen 20 mg vial. Here it is dissolved in bacteriostatic water, a 0.9% benzyl alcohol solution, with the peptide making up 0.2% w/v or less. The peptide is not classified on the safety data sheet. The preservative is: benzyl alcohol is harmful if swallowed or inhaled, irritates the eyes and can sensitise skin.
What the research covers
Bronchogen's own research is cellular and computational. In cultures of human embryonic bronchial cells, it raised expression of the differentiation factors CXCL12 and Hoxa3 in the epithelial cells, and the increase was greater in late-passage cultures1. Docking models from Khavinson's group put AEDL on the DNA sequence ctcc, a prediction rather than a measured binding2. None of this work involved the nose, and the bronchial cells were grown in dishes, not reached through an airway.
Interest in spraying peptides into the nose belongs to the drug delivery field. Writing in 2002, Illum surveyed the nasal formulations that companies were then building for generic drugs and peptides, and reviewed the discovery of a direct nose-to-brain transport route through the olfactory region, with early proof-of-concept examples3. It does not discuss Bronchogen or any Khavinson peptide, and nothing in these references measured how AEDL crosses the nasal lining or where it goes afterwards.
Frequently asked questions
Is the spray the same Bronchogen as the vial?
Yes. Ala-Glu-Asp-Leu is the peptide in every Bronchogen listing, at 20 mg each. What differs is the form: dry, freeze-dried powder in the vial, kept at −20 °C, against a sterile bacteriostatic water solution in the bottle, kept refrigerated and never frozen.
What is the solution made of?
Water, benzyl alcohol at 0.9% as the preservative, and 20 mg of Bronchogen, which the safety data sheet puts at 0.2% w/v or below. Nothing else is listed on the sheet, and the peptide amount is printed on the bottle label.
Has Bronchogen been studied by the nasal route?
Not in the references checked for this page. The Bronchogen studies used cell cultures, purified DNA and computer models, and the nasal delivery review cited here concerns drugs and peptides in general without mentioning Bronchogen.
Does the spray hold AEDL or ADEL?
AEDL, Ala-Glu-Asp-Leu, as stated on the certificate for the peptide lot used to fill it. Papers on bronchogen do not all agree on the order of the glutamic and aspartic acid residues, and because both orders weigh the same, check the sequence named in any study you compare against.
Is Bronchogen nasal spray intended for people?
No. SCALE Performance supplies the spray to laboratories as a research material. Neither the FDA nor any other regulator has approved Bronchogen for human or veterinary use, so it is never to be sprayed into, or otherwise given to, a person or an animal.
References
- Khavinson VKh, Linkova NS, Polyakova VO, et al. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. 2012;153(1):148-51. DOI · PubMed
- Khavinson VK, Lin'kova NS, Tarnovskaya SI. Short Peptides Regulate Gene Expression. Bull Exp Biol Med. 2016;162(2):288-292. DOI · PubMed
- Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today. 2002;7(23):1184-9. DOI · PubMed
For laboratory research use only. Not for human or veterinary consumption. Products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure or prevent any disease.